Maximiano Ringa

Dr. Maximiano Ringa


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NPNahuel Paesano
Nahuel Paesano
JCJuan Camean
Juan Camean
MRMaximiano Ringa
Maximiano Ringa
Maximiliano Lopez SilvaMaximiliano Lopez Silva
Maximiliano Lopez Silva
GKGuido Koren
Guido Koren
JMJuan Morote
Juan Morote
Objectives: To externally validate the Barcelona Predictive Models (BCN-PM 1 and 2) for detecting csPCa in an Ibero-American population. BCN-PM 1 was designed to reduce magnetic resonance imaging (MRI) use, whereas BCN-PM 2 aims to decrease unnecessary prostate biopsies. Methods: This prospective, multicenter study included 661 men with suspected PCa recruited in 2025 across three Ibero-American centers. All participants underwent MRI followed by targeted biopsies of lesions with the Prostate Imaging–Reporting and Data System (PI-RADS) ≥ 3, along with systematic biopsy. When PI-RADS lesions were <3, only systematic biopsies were performed. CsPCa was defined as International Society of Urological Pathology Grade Group ≥ 2. BCN-PM 1 incorporates age (years), family history of PCa (no vs. yes), prior negative prostate biopsy (no vs. yes), digital rectal examination (DRE: normal vs. suspicious), and prostate volume-derived estimation by DRE (small, median, or large). BCN-PM 2 includes age, family history of PCa, prior negative prostate biopsy, prostate volume measured by MRI (mL), and PI-RADS score (1–5). Results: The rate of csPCa detection was 53.7%. Both models demonstrated good calibration with strong agreement between predicted probabilities and observed csPCa rates. BCN-PM 1 closely followed the reference line, with minor deviations at higher predicted probabilities, whereas BCN-PM 2 showed modest departures at the extremes of risk. The area under the curve was 0.740 (95% CI 0.702–0.777) for BCN-PM 1 and 0.803 (95% CI 0.769–0.836) for BCN-PM 2 (p < 0.001). Decision curve analysis demonstrated a net benefit for both models compared with strategies of biopsy in all or no men. BCN-PM 2 showed greater net benefit than BCN-PM 1. At 95% sensitivity, BCN-PM 1 reduced MRI requests by 10.6%, while BCN-PM 2 avoided 19.4% of unnecessary biopsies. The sequential use of BCN-PM 1 and 2 resulted in a 10.6% reduction in MRI exams and a 23.1% reduction in biopsies, at the cost of missing 8.4% of csPCa cases. The performance of the biopsy improved from 53.7% to 64.0% (p < 0.001). Conclusions: BCN-PM1 and BCN-PM 2 were successfully validated in an Ibero-American population.

7 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NPNahuel Paesano
Nahuel Paesano
VCVioleta Catalá
Violeta Catalá
JCJuan Camean
Juan Camean
TOTomás Eduardo Olmedo
Tomás Eduardo Olmedo
JGJoaquín Ignacio Gurovich
Joaquín Ignacio Gurovich
JMJuan Morote
Juan Morote
Background: External validation of predictive models is needed in new populations after their implementation. Objective: We aimed to validate and compare the performance of the BCN-MRI PM and ERSPC-MRI PM in an Ibero-American population. Methods: We conducted a retrospective analysis of 540 men with suspected PCa who underwent MRI and prostate biopsy in 2025. Individual csPCa risk estimates were calculated using the online calculators for the BCN-MRI PM and ERSPC-MRI PM. The reference standard outcome was the rate of avoided biopsies. Calibration, discrimination of csPCa, net benefit, and clinical utility were analyzed with R software. Results: All participants underwent MRI and prostate biopsy. The median age was 66 years (95% CI 61–71). The overall csPCa detection rate was 55.7%. The BCN-MRI PM demonstrated good calibration, with close agreement between predicted and observed csPCa probabilities, whereas the ERSPC-MRI PM underestimated risk in the intermediate-probability range. Discrimination for csPCa was significantly better with the BCN-MRI PM (AUC, 0.807; 95% CI 0.771–0.843) than with the ERSPC-MRI PM (AUC, 0.764; 95% CI 0.724–0.803; p < 0.001). Decision curve analysis showed a greater net benefit for the BCN-MRI PM than for the ERSPC-MRI PM and the strategy of biopsying all men. Clinical utility curves demonstrated a more favorable balance between avoided biopsies and missed csPCa cases across threshold probabilities. At a sensitivity of 95%, the BCN-MRI PM achieved a specificity of 38.9% (95% CI, 32.5–45.1%) compared with 30.1% (95% CI, 24.6–35.7%) for the ERSPC-MRI PM, avoiding 21.5% and 16.3% of biopsies, respectively (p = 0.043). The performance of both models was also evaluated according to PI-RADS category and participating center. Conclusions: In this Ibero-American cohort, the BCN-MRI PM demonstrated superior calibration and overall clinical performance compared with the ERSPC-MRI PM.

13 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VDVictoria Diaz-Zorita
Victoria Diaz-Zorita
PHPablo Sabeh Hamdan
Pablo Sabeh Hamdan
MRMaximiano Ringa
Maximiano Ringa
AJAlberto Jurado
Alberto Jurado
HPHernando Rios Pita
Hernando Rios Pita
Gonzalo Juan VitaglianoGonzalo Juan Vitagliano
Gonzalo Juan Vitagliano
Introduction: Accurate preoperative characterization of renal tumor anatomy is essential for partial nephrectomy. Although the R.E.N.A.L. nephrometry score is widely used to assess tumor complexity, its interpretation using conventional computed tomography (CT) may vary among observers. We evaluated whether three-dimensional (3D) reconstruction improves the consistency of preoperative R.E.N.A.L. score assessment. As a secondary objective, perioperative outcomes were compared between patients planned with CT plus 3D reconstruction and those planned with CT alone. Materials and Methods: A retrospective observational study included 55 patients who underwent partial nephrectomy between March 2023 and March 2025. Three experienced urologists independently assigned R.E.N.A.L. nephrometry scores using conventional CT and CT-based 3D reconstructions. Interobserver and intraobserver agreement were assessed using Pearson correlation coefficients, weighted Cohen's kappa, and Fleiss' kappa. Perioperative outcomes were analyzed in a comparable control cohort planned using CT alone. Results: Three-dimensional reconstruction demonstrated greater interobserver agreement than CT alone for both numerical R.E.N.A.L. scores (57% vs. 43%) and risk categorization (72% vs. 62%). Fleiss' kappa indicated very good agreement with 3D reconstruction (κ=0.804) compared with moderate agreement using CT (κ=0.562). Intraobserver agreement between CT and 3D reconstruction was moderate. No significant differences were observed in operative time, warm ischemia time, blood loss, postoperative renal function, or complication rates. Hospital stay was slightly longer in the 3D group. Conclusions: Three-dimensional reconstruction may represent a valuable complementary tool for improving the consistency of preoperative R.E.N.A.L. nephrometry score assessment. Although greater agreement did not translate into measurable perioperative benefits in this cohort, more reproducible anatomical characterization may contribute to a more standardized framework for surgical planning before partial nephrectomy.

16 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
NPNahuel Paesano
Nahuel Paesano
VCVioleta Catalá
Violeta Catalá
JCJuan Camean
Juan Camean
TOTomás Eduardo Olmedo
Tomás Eduardo Olmedo
JGJoaquín Ignacio Gurovich
Joaquín Ignacio Gurovich
JMJuan Morote
Juan Morote
Background: The ERSPC-MRI PM is of the most widely used and extensively validated predictive model in Europe. Objective: We aimed to validate and compare the perfor-mance of the BCN-MRI PM and ERSPC-MRI PM in an Ibero-American population. Met-hods: We conducted a prospective analysis of 540 men with suspected PCa who underwent MRI and prostate biopsy in 2025. Individual csPCa risk estimates were cal-culated using the online calculators for the BCN-MRI PM and ERSPC-MRI PM. Results: The overall csPCa detection rate was 55.7%. The BCN-MRI PM demonstrated good cali-bration, with close agreement between predicted and observed csPCa probabilities, whereas the ERSPC-MRI PM underestimated risk in the intermediate-probability range. Discrimination for csPCa was significantly better with the BCN-MRI PM (AUC, 0.807; 95% CI 0.771-0.843) than with the ERSPC-MRI PM (AUC, 0.764; 95% CI 0.724-0.803; p < 0,001). Decision curve analysis showed a greater net benefit for the BCN-MRI PM than for the ERSPC-MRI PM and the strategy of biopsying all men. Clinical utility curves demon-strated a more favorable balance between avoided biopsies and missed csPCa cases across threshold probabilities. At a sensitivity of 95%, the BCN-MRI PM achieved a specificity of 38.9% (95% CI, 32.5%–45.1%) compared with 30.1% (95% CI, 24.6%–35.7%) for the ERSPC-MRI PM, avoiding 21.5% and 16.3% of biopsies, respectively (p = 0.043). The performance of both models was also evaluated according to PI-RADS category and participating center. Conclusions: In this Ibero-American cohort, the BCN-MRI PM demonstrated superior calibration and overall clinical performance compared with the ERSPC-MRI PM.